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Virulencelence associated genes in porcine reproductive and respiratory syndrome virus
(PRRSV), a series of chimeric viruses were generated where speciﬁc genomic regions of a highly virulent
PRRSV infectious clone (FL12) were replaced with their counterparts of an attenuated vaccine strain (Prime
Pac). Initial genome-wide scanning using a sow reproductive failure model indicated that non-structural
(ORF 1a and 1b) and structural (ORF2-7) genomic regions appear to be sites where virulence determinants
of PRRSV may reside. These results thus conﬁrm the multigenic character of PRRSV virulence. Additional
chimeras containing each individual structural ORFs (2 through 7) of Prime Pac and ORF5 of Neb-1 (parental
strain of Prime Pac) within the FL12 backbone were generated and tested individually for further mapping of
virulence determinants. Our results allow to conclude that NSP3–8 and ORF5 are the location of major
virulence determinants, while other virulence determinants may also be contained in NSP1–3, NSP10–12
and ORF2.
© 2008 Elsevier Inc. All rights reserved.Introduction
Porcine reproductive and respiratory syndrome (PRRS) is an
economically important disease of swine worldwide, characterized
by reproductive failure such as late-termabortions in sows, respiratory
disease, and increasedmortality in young pigs. A recent analysis of the
economic impact of PRRS indicates that losses due to this disease are
estimated to be greater than $ 560 million each year in the United
States alone (Neumann et al., 2005). The causative agent, PRRSV,
belongs to the family Arteriviridae in the order Nidovirales (Cavanagh,
1997; Posthuma et al., 2006) that also includes lactate dehydrogenase-
elevating virus (LDV), equine arteritis virus (EAV), and simian
hemorrhagic fever virus (SHFV). The genome of PRRSV consists of a
linear, positive-stranded, single molecule of RNA of approximately
15 kb in length, possessing a 5′ cap structure and 3′ poly (A) tail. The
genome contains 9 open reading frames (ORFs) ﬂanked by untrans-
lated regions (UTRs) at the 5′- and 3′-termini (Conzelmann et al., 1993;
Meulenberg et al., 1993; Snijder and Meulenberg, 2001; Wu et al.,
2005). The ﬁrst 2 ORFs located at the 5′-end of the viral genome (ORFs
1a and ORF1ab) occupy around 80% of the viral genome and encode
viral non-structural proteins (NSPs) which are involved in viral
polyprotein processing and replication (Bautista et al., 2002; Meulen-
berg et al.,1993; Snijder andMeulenberg,1998, 2001). The remaining 7
ORFs (ORF2a, 2b, 3–7) at the 3′-end of the viral genome encode viral
structural proteins and are translated from a co-terminal nested set ofl rights reserved.sub-genomic mRNAs with a common leader sequence at the 5′-end
(Dea et al., 2000;Meulenberg et al.,1995a,1997;Wu et al., 2001, 2005).
PRRSV strains circulating in the ﬁeld are highly diverse. Some
studies have compared the pathogenicity of PRRSV strains and have
described a range of degree of virulence among PRRSV strains (Halbur
et al., 1995, 1996). However, a typical avirulent or attenuated PRRSV
phenotype corresponds to some of the live commercial vaccines that
have been developed (Gorcyca et al., 1995). These modiﬁed live
vaccines are considered to be the only PRRS vaccines with well
documented capacity to induce effective protection against PRRSV
infections (Osorio et al., 1998; Zuckermann et al., 2007), especially if
the challenge and vaccine strains maintain close homology. The Prime
Pac (PP) attenuated vaccine has been previously demonstrated to
control PRRS effectively in both reproductive and respiratory disease
models (Hesse, 1996a,b; Hesse et al., 1997). This PP and other
attenuated PRRSV strains used for vaccination were developed by
conventional methodology involving multiple serial passages in a
continuous cell line, a process that is concomitant with a progressive
loss of the in vivo virulent phenotype.
Previous studies, based exclusively on sequence comparisons
between parental virulent and their avirulent derivative strains have
suggested that important determinants of virulence would be
scattered throughout the PRRSV genome, and may include: 5′ UTR,
ORFs 1a (NSP2), 1b (NSP10), 2, 3, 4, 5 and 6 (Allende et al., 2000;
Grebennikova et al., 2004; Madsen et al., 1998; Oleksiewicz et al.,
1999; Oleksiewicz et al., 2002; Storgaard et al., 1999; Yang et al., 1998;
Yuan et al., 2001). Furthermore, many of the mutations are not
necessarily related to in vivo virulence but rather to the adaptation of
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priori inferences, the actual molecular basis for the virulence and
attenuation of PRRSV still needs to be determined. Live attenuated
vaccines can revert back to virulence, mainly due to the natural
properties of RNAviruses to easily mutate under selective pressures. A
number of vaccine-related revertants have been previously reported
(Botner et al., 1999, 1997; Madsen et al., 1998; Nielsen et al., 2001,
2002; Stadejek et al., 2002; Storgaard, Oleksiewicz, and Botner, 1999);
thus the understanding of the molecular basis of attenuation of PRRSV
virulence is critical for future generation of novel, more rationally
attenuated PRRSV vaccines.
Our laboratories have previously generated and characterized a
highly virulent PRRSV strain (vFL12) derived from a full-length PRRSV
infectious cDNA clone (FL12) (Truong et al., 2004), and more recently
we constructed an infectious clone of attenuated PP vaccine strain
(vPP18) (Kwon et al., 2006). Sequence comparisons indicated that
these two strains exhibit approximately 90% homologywith a number
of sequence differences distributed throughout the genome. More-
over, the biological properties of these infectious clone-derived
viruses were substantiated in either a young pig (vFL12) or a pregnant
sow models (vFL12 and vPP18) by unequivocally reproducing the
highly virulent and attenuated phenotypes of parental viruses
respectively (Kwon et al., 2006). In the present study, we describe
the generation of a series of chimeric viruses established between two
different PRRSV strains of divergent virulence phenotypes and their
use for in vivo studies (sow reproductive failure model) to determine
the molecular basis of the PRRSV virulence and attenuation. Our
results indicate that PRRSV virulence is multigenic, with the PRRSV
virulence residing in both the non-structural and structural genes.
Among the non-structural genes, NSP3–8 regions are the location of
major virulence determinants while ORF5, encoding glycoprotein (GP)
5, is the principal structural determinant of virulence.
Results and discussion
Construction of chimeric clones and recovery of viable chimeric viruses
By systemically exchanging genomic regions and generating a
series of chimeric viruses spanning the entire genome of PRRSV, weFig. 1. Construction of chimeric PRRS viruses for genome-wide scanning for genes involved i
colored boxes represent the regions of parental viruses vFL12 (black) and Prime Pac (gray), re
depicted. The designation of each chimeric virus is shown on the left.conﬁrmed speciﬁc regions that are associated with virulence. Similar
approaches were reasonably successful to demonstrate the determi-
nants of virulence, plaque phenotype, pathogenesis and immuno-
genicity in several other viruses, such as swine vesicular disease virus
(Kanno et al., 1999), porcine circovirus type 1 and 2 (Fenaux et al.,
2003), classical swine fever virus (Risatti et al., 2005), foot- andmouth
disease virus (Beard and Mason, 2000), simian immunodeﬁciency
virus (Haddrick et al., 2001) and vaccinia virus (Kim et al., 2003).
Importantly, a recent report validates the development of chimeras
between a virulent and a vaccine strain of PRRSV and the study of the
biological properties of these chimeras by inoculation of young pigs.
The ﬁndings suggest that both structural and non-structural regions of
PRRSV genome may be important for virulence (Wang et al., 2008).
With the highly virulent FL12 full-length infectious clone serving
as the genomic backbone, a series of full-length chimeric cDNA clones
containing various genomic regions spanning the entire genome of PP
vaccine strain were generated. These clones, shown in Fig. 1, contain:
5′ UTR and NSP1 and part of NSP2 (cP5U.NSP1.2); part of NSP2 and
part of NSP3 (cPNSP2.3); part of NSP3 to NSP8 (cPNSP3.8); NSP9
(cPNSP9); NSP10 to NSP12 (cPNSP10.12); ORF3 to 7 and 3′ UTR
(cPORF3.3U) genes; and the entire region spanning all the structural
genes and 3′ UTR (cPORF2.3U) of the PP vaccine virus genome (Fig. 1).
Likewise, additional chimeric viruses containing individual structural
genes of PP vaccine within the context of the FL12 genomic backbone
were also constructed. In these cases a full-length infectious clone
(PP18) derived from PP vaccine virus described previously (Kwon
et al., 2006) was used to provide genomic components of PP vaccine
virus to the FL12 backbone in order to generate chimeric clones
containing individual structural genes of PP vaccine virus or ORF5 of
Neb-1, the parental strain of PP as shown in Fig. 2. This approach
generated a series of chimeric strains, which represent respectively:
ORF2 (cPORF2), ORF3 (cPORF3), ORF4 (cPORF4), ORF5 (cPORF5),
ORF6 (cPORF6), and ORF7 gene and 3′ UTR (cPORF7.3U) of PP vaccine
virus genome as well as the ORF5 (cNORF5) of Neb-1 (Fig. 2).
All the individual chimeric clones were conﬁrmed by sequencing
and a number of nucleotide changes and resulting amino acid
alterations including introduced restriction endonuclease (RE) sites
were observed throughout the genome as described previously (Kwon
et al., 2006) (Table 2). Table 2 summarizes the nucleotide changesn attenuation. The genome organization of PRRSV is shown at the top of the ﬁgure. The
spectively. Corresponding restriction sites and nucleotide numbers used for cloning are
Fig. 2. Construction of single gene chimeric PRRS viruses within structural regions. The genome organization of PRRSV is shown at the tope of the ﬁgure. The boxes with different
color represent the regions of parental viruses vFL12 (black), vPP18 (gray) and Neb-1 (white) respectively. Corresponding restriction sites and nucleotide numbers used for cloning are
depicted. The designation of each chimeric virus is shown on the left.
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replacement and their predicted amino acids changes. Overall, 14
nucleotide changes resulted in 4 non-conservative (Ala782Val,
Ser254Asn, Leu48Thr, Trp256Arg) and 1 semi-conservative
(Ser171Gly) amino acid changes within ORF 1a, 2, 3 and 5 regions
(Table 2). The full-length chimeric cDNA clones were linearized by
digestion with AclI, as described in Materials and methods, and used
for in vitro transcription followed by electroporation into MARC-145
cells. Viable chimeric viruses were recovered as described previouslyFig. 3. Growth kinetics of parental and chimeric viruses. The viable chimeric viruses along wit
145 cells at a MOI of 10. Culture supernatant was collected at 6, 12, 24, 48 and 72 h PI. The
endpoint. Results shown are themean values of three independent experiments and error ba
3B) were used for this analysis (except for Neb-1 and cNORF5).(Kwon et al., 2006; Truong et al., 2004). By sequence analysis, we
conﬁrmed that the genomic sequences of the rescued viruses were
derived from their corresponding chimeric clones and maintained the
nucleotides changes.
In vitro growth properties of chimeric viruses
All the chimeric constructs described above and shown in Figs. 1
and 2 resulted in viable viruses. The growth kinetics of the chimerash the parental viruses were used to analyze their growth kinetics when infecting MARC-
virus titers were determined by Reed and Muench calculation of the tissue culture 50%
rs represent the standard deviation. The viruses depicted in Fig. 1 (Fig. 3A) and Fig. 2 (Fig.
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or vPP18, using MARC-145 cells as previously described (Kwon et al.,
2006). The growth kinetics shows that the yields of the chimera
cultures were different and that most chimeric viruses had relatively
impaired growth compared to parental viruses. The replicationpattern
and the time to reach peak viral titers were somewhat delayed and in
some cases (i.e. cPNSP9, cPNSP10.12) extended to 72 h post infection
(PI) (Fig. 3). However the impaired growth in cell culture did not seem
to affect viral replication in vivo. Based on kinetics of seroconversion by
ELISA, the chimeric viruses replicated as efﬁciently as wild type (wt)
upon inoculation of pregnant sows (data not shown).
In vivo virulence phenotype of the chimeric viruses in sow reproductive
failure model
Primary genome-wide scanning of PP vaccine strain indicates that major
determinants of attenuation would reside within certain non-structural
(NSP3-8) and structural (ORF2–3′ UTR) regions
Upon inoculation of sows at 90th day of gestation, the number of
viable offsprings at birth and upon weaning at 15 days of age was
evaluated. Other parameters, including daily clinical signs and rectal
temperatures, total antibody response and viremia in the sows were
also evaluated as described previously (Kwon et al., 2006; Osorio
et al., 2002). As typical for the swine reproductive failure model
when using the FL12 infectious clone or its parental strain (Osorio et
al., 2002), no speciﬁc clinical signs other than lack of appetite,
lethargy and slight fever shortly after infection and prior to
reproductive failure, which typically takes place at a later time
post inoculation, shortly before or at normal farrowing time were
noticed in any group of sows inoculated with all of the different
strains throughout the experimental period. The vFL12-inoculated
sows conﬁrmed a completely pathogenic phenotype, with 100%
mortality of the piglets and the PP vaccine virus-inoculated sows
showed normal range of survival rate with 77% (Table 3) in both
cases consistent with our previous reports (Kwon et al., 2006). In the
primary genome-wide scanning, most important genomic regions
contributing to PRRSV virulence were mapped within the NSP3 to 8
and ORF2 to 7 as reﬂected in the sows inoculated with cPNSP3.8,
cPORF2.3U and cPORF3.3U chimeric viruses exhibiting signiﬁcant
piglet survival rates of 75%, 69% and 71%, respectively. While NSP9
(cPNSP9) could be ruled out as an important virulence determinant,
it should be noted that most of NSP-encoding regions seemed to play
a relative role in virulence, as exhibited by the sows inoculated with
cP5U.NSP1.2 (51%), cPNSP2.3 (56%) and cPNSP10.12 (56%) chimeric
viruses (Table 3).
Amongst the PRRSV structural genes, the ORF5 contributes primarily to
PRRSV virulence
As a result of this initial genome-wide scanning for PRRSV
virulence markers, we concluded that the NSP3-8 segment and the
structural protein-coding area are the genomic regions where possible
major virulence determinants seem to be located. For practical
reasons, we focused on generating individual structural gene chimeras
based on the availability of our intermediate plasmid encompassing
the majority of structural ORFs and entire 3′ UTR derived from the
FL12 (Ansari et al., 2006). By analyzing the virulence phenotypes of the
single structural gene chimeras using pregnant sows reproductive
failure model, it turned out that ORF5 (cPORF5), reaching 44% survival,
principally contributes to virulence within structural regions. This
result strongly suggests that the GP5 of PP contains a major virulence
determinant which leads to signiﬁcant increase in survival rate
observed with cPORF5-inoculated sows.
To further substantiate this conclusion we also generated a
chimera which includes the ORF5 of wt virulent parental strain of
PP (Neb-1) within the background of FL12 (Fig. 2). The in vivo testing
of this construct (cNORF5, Table 4) allowed us to conﬁrm that thischimera, which replaces the ORF5 of PP by its respective wt version,
retains virulence at a level equivalent to that of wt FL12. This
observation rules out the possibility that the attenuation resulting
after gene swapping for the construction of cPORF5 (Table 4) was
possibly caused by the mere incompatibility or imperfect matching of
viral proteins encoded by genes derived from the two different non-
homologous strains composing the chimera (FL12 and PP) rather than
being caused by the true attenuation on a virulence determinant. The
cNORF5 construct demonstrated its in vivo pathogenic properties in
the sow reproductive failure model, which clearly supports the
contribution of wt ORF5 in virulence. The scores exhibited by vFL12
(0%) and cNORF5 (7%) demonstrate in both cases that the ORF5 gene
should be exclusively responsible for the signiﬁcant differences in
reproductive performance between both FL12 and cNORF5 (each of
deﬁnitely virulent phenotype) and the partially attenuated phenotype
of cPORF5 (Table 4). From all of the above it can be concluded that,
through the process of attenuation in vitro that gave origin to the PP
vaccine strain, one of the main factors that led to attenuation of PRRSV
came from sequence alteration of certain virulence determinant
contained in GP5.
Interestingly only 2 amino acid differences (Phe17Leu and
Ser171Gly) were found in the entire coding sequences of GP5 between
PP vaccine and Neb-1 wt virulent strains (data not shown). We
introduced an RE site at position 171 of PP which led to generation of a
mutation from Ser to Gly as shown in Table 2, thus only one amino acid
change at position 17 in cNORF5 seems to potentially be involved in
virulence. Future single point mutation studies should then examine if
indeed this single Phe17Leu is responsible for the ORF5 contribution
to PRRSV virulence.
The ORF5 of the PRRSV genome encodes the major viral envelope
protein GP5, which is a glycosylated transmembrane protein of
approximately 25 kDa (Dea et al., 2000; Gagnon et al., 2003;
Meulenberg et al., 1995b). Like EAV and LDV, the PRRSV GP5 and
matrix (M) protein interact and form heterodimers, which may play a
critical role in virus assembly but for which the mode of interaction
has not been demonstrated yet (Delputte et al., 2002; Mardassi,
Massie, and Dea, 1996). It has been proposed that the GP5 is involved
in the entry of virus into the host cells, presumably by interacting with
the host cell receptor sialoadhesin, especially for macrophages
(Delputte and Nauwynck, 2004). The GP5 is considered to be
important in the infection process because the presence of a major
neutralization epitope in the N-terminal ectodomain that might be
involved in receptor recognition (Ostrowski et al., 2002). Moreover,
recent studies from our laboratories (Ansari et al., 2006) provide
evidence that glycosylation of GP5 of PRRSV play an important role in
escaping or minimizing virus-neutralizing antibody response by the
glycan-shielding mechanism (Johnson et al., 2003; Wei et al., 2003).
This glycan shieldingmechanism is also observed in LDV (Chen, Li, and
Plagemann, 2000), hepatitis B virus (HBV) (Lee et al., 2003), simian
immune deﬁciency virus (SIV) (Reitter, Means, and Desrosiers, 1998),
inﬂuenza virus (Skehel et al., 1984), and human immune deﬁciency
virus (HIV) (Wei et al., 2003).
With the possible exception of ORF2, the rest of PRRSV structural
genes or sequences (ORFs 3, 4, 6, 7 and 3′ UTR) did not contribute
signiﬁcantly to virulence, with all of them reaching negligible survival
rates (Table 4). It is interesting to observe that the score attained by
cPORF2, which reached a 24% survival, may indicate a partial role of
this gene in PRRSV virulence although not to a level as signiﬁcant as
ORF5. Future studies may be necessary to elucidate this possible role
of ORF2 in PRRSV virulence.
The use of our highly virulent infectious clone (FL12) as a backbone
to construct chimeric viruses has several advantages. First, the highly
pathogenic properties of vFL12 in either young pigs or sows
reproductive failure model are easily reproducible and distinguishable
from the attenuated phenotype. Secondly, vFL12 grows well in vitro in
both MARC-145 and PAM cells. The FL12 clone can be directly
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consistently rescue chimeric viruses with relatively high titer. Lastly,
because the attenuated PP vaccine infectious clone PP18 was
constructed by using the intermediate chimeric clones within the
FL12 backbone (Kwon et al., 2006), a number of cloning sites of PP18
are shared with FL12, thus both clones being easily interchangeable.
The logical continuation of our study on the contribution of the
ORF5 gene to PRRSV virulence should consist of uncovering the
precise role of single residue(s) for essential virulence within this
gene. This will be pursued by site-directedmutagenesis followed by in
vitro and in vivo characterization. More importantly, other virulence
determinants should be identiﬁed within NSP3 to 8 regions, another
cluster of important virulence maker candidates, whose individual
characterization will certainly elucidate the reconstitution of full in
vivo virulence of attenuated strains of PRRSV.
Materials and methods
Cells and viruses
The MARC-145 cells, a sub-clone of MA-104 cells (Kim et al., 1993)
were propagated and maintained as described previously (Ansari
et al., 2006; Truong et al., 2004). These cells were used for RNA
electroporation, virus titration and viral growth kinetics. Second
passage (P2) of vFL12 (Truong et al., 2004) and PP vaccine virus
(obtained from a commercial batch of Prime Pac vaccine marketed in
1997, Schering-Plough Co.) and ﬁrst passage (P1) of vPP18 were used
for growth kinetics and animal inoculation. For the construction of
recombinant chimeric viruses, stocks of comparable titers derived
from passages 1 and 3 were only used. The PRRSV Neb-1 strain
(Hesse, 1996a), parental virus from which PP virus was derived, was
obtained by courtesy of Dr K. Lager (NADC,USDA/ARS, Ames, Iowa).
Preparation of single genomic fragments of PP strain to develop chimeras
The MARC-145 cells were infected with PP vaccine virus (P2) at a
multiplicity of infection (MOI) of 0.1 and culture supernatant was
collected at 48 h post infection (PI). The culture supernatant was
brieﬂy clariﬁed by centrifugation at 3000 ×g for 10 min and the virus
was pelleted by ultracentrifugation at 100,000 ×g on a 15% sucrose
cushion for 2 h. The virus pellet was resuspended in PBS and viral RNA
was extracted with TRIzol LS (Invitrogen), as per manufacturer'sTable 1
Primers used for the development of chimeric constructs
Chimeric Constructs Primer Sequencea
cP5U.NSP1.2 T7P+1F 5′ ATATAAGCTTCGGACCGTAATACGACTCACTATAGG
cP5U.NSP1.2 P2546R 5′ CTGGGCGTTGACTAGTTTCAGCA 3′
cPNSP2.3 P2524F 5′ TGCTGAAACTAGTCAACGCCCAG 3′
cPNSP2.3 P4457R 5′ CGACCTGGTCGCACGCGTAAAAGG 3′
cPNSP3.8 P4434F 5′ CCTTTTACGCGTGCGACCAGGTCG 3′
cPNSP3.8 P7749R 5′ GTAACAACCAACCCGCCGCGACCAC 3′
cPNSP9 P7635F 5′ GACAAACTCCAGGACCTGACTAAG 3′
cPNSP9 P8898R 5′ GTGGAGCGATCGCAGGATGCAAG 3′
cPNSP10.12 P8880F 5′ CATCCTGCGATCGCTCCACACCTGC 3′
cPNSP10.12 P12257R 5′ GCTCAGGGTGAAAGGTAGGGCG 3′
cPORF2/cPORF2.3U P11691F 5′ GCAACAGAAGAGTTGTCGGGTCC 3′
cPORF2 P12842R 5′ CCGTGAGTTCGAAGGAAAAATTGCCCC 3′
cPORF3/cPORF3.3U P12816F 5′ GGGGCAATTTTTCCTTCGAACTCACGG 3′
cPORF2.3U/cPORF3.3U A70R 5′ CACACTTAATTAACGT(70)AATTTCGGCCGCATG 3′
cPORF4/cPORF5/cNORF5 P13464F 5′ GACACCCGTGTACATCACCA 3′
cPORF3 P13481R 5′ GTGATGTACACGGGTGTCCCTAT 3′
cPORF4 P13969R 5′ GACAAAAGTCTCCACTGCCCAATC 3′
cPORF6 P14291F 5′ GAGGTCGAAGGTCACCTGATCGA 3′
cPORF5/cNORF5 P14313R 5′ TCGATCAGGTGACCTTCGACCT 3′
cPORF6 P14971R 5′ CTGGTTCTGCTGGGCGATGATC 3′
a T7 RNA polymerase promoter sequences are shown in bold italics. Underlined sequences
and full-length cDNA assembly. Nonviral sequences are in bold-face type.
b Nucleotide position within the NVSL 97-7895 PRRSV isolate (parental strain of FL12 infrecommendations. The viral RNA was resuspended in nuclease-free
water and either directly used for RT-PCR or stored at −80 °C in small
aliquots. The cDNA was synthesized by Superscript III (Invitrogen)
using speciﬁc reverse primers and subsequently used to generate
various sizes of individual PCR fragments as shown in Figs. 1 and 2
using the primer sets (Table 1). The PCR was carried out using a
mixture of Taq (NEB) and PFU (Stratagene) polymerases to enhance
the ﬁdelity during the DNA synthesis.
Construction of full-length chimeric cDNA clones
Full-length FL12 (Truong et al., 2004) and PP18 (Kwon et al., 2006)
cloneswere utilized as either genomic backbones (FL12) or gene donor
(PP18) to construct chimeric clones. First, to make chimeric clones
covering multiple genes derived from the PP vaccine virus strain, a
series of PCR products, which contain naturally present or deliberately
introduced RE sites (Table 1), RsrII, SpeI,MluI, Pmel, SgfI, EcoRV, BssHII,
BstBI and PacI, were used to replace the corresponding regions of FL12
clone as described previously (Kwon et al., 2006) (Fig. 1). In addition,
the construction of single gene chimeric clones comprising individual
structural protein encoding genes from either the PP vaccine virus,
vFL12 or the ORF5 of Neb-1 strain, additional RE sites (Tables 1 and 2),
BsrGI and BstEII were incorporated or NruIwas utilized to facilitate the
fragment exchange in a similar manner (Fig. 2). The target genes were
either directly cloned into full-length FL12 or into an intermediate
plasmid encompassing themajority of ORF2, complete ORFs 3 to 7, and
the entire 3′UTRderived from the FL12 as described previously (Ansari
et al., 2006). It should be noted that, due to the overlapping character of
the PRRSV structural genes, and in order to avoid adding additional
non-viral sequences to our constructs, these single gene chimeric
constructs included most but not all the corresponding full sequence
for each gene. The percentage of authentic gene represented in each
case ranges from 57% to 100% (ORF2: 98%, ORF3: 82%, ORF4: 57% (most
impacted by the overlapping character of the PRRSV structural genes),
ORF5: 79%, ORF6: 85%, and ORF7: 100%). All generated chimeric cDNA
clones were conﬁrmed by sequence analysis using the appropriate
primers in each case for both FL12 and PP18.
In vitro transcription, RNA electroporation, and virus recovery
The full-length chimeric cDNA clones were digested with AclI
(FL12-based clone) or PacI (PP18-based clone) to linearize and theViral genome Positionb
ATGACGTATAGGTGTTGGCTCTATGCCATGACATTTGTATTG 3′ 1–42
2524–2546
2524–2546
4434–4457
4434–4457
7725–7749
7659–7682
8876–8898
8880–8904
12260–12281
11715–11737
12816–12842
12816–12842
15399–15419
13464–13483
13459–13481
13970–13993
14291–14313
14292–14313
14974–14995
represent restriction endonuclease recognition sites utilized in exchanges of amplicons
ectious clone) (Truong et al., 2004). GenBank accession number is genbank:AY545985.
Table 3
Viability scores of offsprings born from sows infected with parental or chimeric viruses
— primary genome-wide scanninga
Viruses Genetic
background
Sow no.a Viability at
Birth 15 days of age Survivalb (%)
Dead Live Live
vFL12 FL12 1 12 3 0 0
2 13 1 0
Prime Pac Prime Pac 1 0 11 9 77⁎
2 0 14 10
cP5U.NSP1.2 FL12 1 1 12 9 51⁎
2 6 6 4
cPNSP2.3 FL12 1 4 12 9 56⁎
2 1 15 9
cPNSP3.8 FL12 1 0 15 12 75⁎
2 3 10 9
cPNSP9 FL12 1 13 3 0 3
2 9 11 1
cPNSP10.12 FL12 1 5 11 10 56⁎
2 5 5 5
cPORF2.3U FL12 1 0 15 9 69⁎
2 2 7 7
cPORF3.3U FL12 1 0 10 10 71⁎
2 3 9 5
a Two sows each per group. Arbitrary numbers.
b Least squares means of each group. The asterisk indicates that the means are
signiﬁcantly different (P≤0.05) than the mean of vFL12 group.
Table 4
Viability scores of offsprings born from sows infected with chimeric viruses
representing single structural genesa
Viruses Genetic
background
Sow no.a Viability at Survivalb
(%)
Birth 15 days of age
Dead Live Live
vFL12 FL12 1 12 3 0 0
2 13 1 0
cPORF2 FL12 1 9 6 4 24
2 7 2 2
cPORF3 FL12 1 15 0 0 7
2 9 5 2
cPORF4 FL12 1 9 1 0 3
2 12 3 1
cPORF5 FL12 1 7 7 4 44⁎
2 3 7 6
cPORF6 FL12 1 8 4 0 7
2 11 4 2
cPORF7.3U FL12 1 13 4 1 6
2 13 2 1
cNORF5 FL12 1 10 4 2 7
2 10 5 0
a Two sows each per group. Arbitrary numbers.
b Least squares means of each group. The asterisk indicates that the means are
signiﬁcantly different (P≤0.05) than the mean of vFL12 group.
Table 2
Nucleotide changes incorporated within the genome of PP vaccine (or PP18) and Neb-1
for the fragment exchange into FL12 and their predicted amino acid changes
Nucleotide
positiona
ORF Genome of
changes
incorporated
Nucleotide
changeb
Amino acid
position
(Protein name)
Amino acid
Change
2534 1a PP G→A 781 (NSP2) Silent
2536 1a PP C→T 782 (NSP2) A→V
4442 1a PP A→G 1453 (NSP3) Silent
8893 1b PP A→C 404 (NSP9) Silent
8896 1b PP T→C 405 (NSP9) Silent
12835 2 PP G→A 254 (GP2) S→N
12839 3 PP T→A 48 (GP3) L→T
12840 2 PP T→C 256 (GP2) W→R
13476 4 PP T→C 78 (GP4) Silent
14300 5 PP A→G 171 (GP5) S→G
14302 5 PP C→T 171 (GP5) Silent
14305 5 PP T→C 172 (GP5) Silent
14302 5 Neb-1 C→T 171 (GP5) Silent
14305 5 Neb-1 T→C 172 (GP5) Silent
a Nucleotide positions are based on the genome of NVSL 97-7895 PRRSV isolate
(Truong et al., 2004) as shown in Table 1.
b The GenBank accession numbers of original nucleotide sequences of PP vaccine,
PP18, and Neb-1 are genbank:AF184212, genbank:DQ779791, and genbank:EU755263,
respectively.
376 B. Kwon et al. / Virology 380 (2008) 371–378DNA was used as templates to generate capped RNA transcripts
using the mMESSAGE mMACHINE Ultra T7 kit as per manufac-
turer's recommendations (Ambion) and as described previously
(Truong et al., 2004). The reaction mixture was treated with DNaseI
to digest the DNA template and extracted with phenol and
chloroform and precipitated with isopropanol. The integrity of the
in vitro transcripts was analyzed by glyoxal agarose gel electro-
phoresis followed by ethidium bromide staining. Sub-conﬂuent
MARC-145 cells seeded 2 days prior to use were trypsinized and
collected for electroporation. About 2×106 cells in 400 μl of
Dulbecco's modiﬁed Eagles medium (DMEM) containing 1.25%
DMSO were electroporated with approximately 5.0 μg of in vitro
transcripts along with 5.0 μg of total RNA isolated from MARC-145
cells by pulsing once using Bio-Rad Gene Pulser Xcell at 225–
250 V, 925–950 μF in a 4.0 mm cuvette. The electroporated cells
were transferred in a DMEM containing 10% FBS and 1.25% DMSO
in a 60-mm cell culture plate for virus recovery and in a separate
plate for immunoﬂuorescence staining. Upon initial development of
cytopathic effect (CPE), the supernatant from the electroporated
cells in 60-mm plate was collected, clariﬁed and passed onto naïve
MARC-145 cells in 100 mm plates to prepare stock virus. The
culture supernatant was recovered when complete CPE was
observed, centrifuged brieﬂy to remove cell debris, and frozen at
−80 °C in small aliquots for further studies.
Viral growth properties and kinetics
Growth properties of parental (vFL12, PP vaccine and vPP18) and
chimeric viruses were compared in MARC-145. For the growth
kinetics, MARC-145 cells were infected with the above-mentioned
viruses at an MOI of 10 and incubated at 37 °C. At various time points
PI, the culture supernatant from infected cells was collected and virus
titer was determined and expressed as tissue culture infectious dose
50 per ml (TCID50/ml).
Animal experiments
Pregnant sows were purchased from a speciﬁc-pathogen-free herd
with a certiﬁed record of absence of PRRSV infection. Their negative
PRRSV infection status was conﬁrmed upon arrival by a commercial
ELISA serology test (IDEXX Labs, Portland, ME). Pregnant sows were
inoculated at 90 days of gestation and the viability scores of offspringsat birth and weaning (at 15 days of age) were evaluated (Osorio et al.,
2002). All animals were tested for anti-PRRSV antibodies by ELISA
(IDEXX Labs, Portland, ME). Two sows per group in each separate
experiment were infected with parental and chimeric viruses (Tables
3 and 4). In all the cases, a total of 2 ml (105.2 TCID50) of virus was
administered intra-nasally with 1 ml delivered into each nostril. The
rectal temperature and clinical signs of the inoculated animals were
monitored daily from 3 days pre-inoculation through farrowing and to
weaning. Viremiawas always measured by regular titration on MARC-
145 cells and in some cases by nested RT-PCR as described previously
(Osorio et al., 2002), using the sera collected at 0–7–14–21 days PI. The
copy numbers of viral RNA from the sera of sowsweremeasured using
a PRRSV real-time quantitative PCR kit (Tetracore, USA).
377B. Kwon et al. / Virology 380 (2008) 371–378Statistical analysis
Viral growth properties in MARC-145 cells between parental and
chimeric viruses were compared by Dunnett's t test and viability
scores of offsprings born from sows infected with parental and
chimeric viruses were analyzed by Duncan's multiple range test using
SAS (version 9.1 for windows; SAS Institute Inc., Cary, NC, USA)
program. A P-value of less than 0.05 was considered signiﬁcant.
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